C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
Go back to C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma| Cache Capital Corp. (NASDAQ: CCCC) | Delayed: 4.12 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.12 | 52 Week High | $0.30 | |||
| Open | $4.12 | 52 Week Low | $0.30 | |||
| Day High | $4.12 | P/E | N/A | |||
| Day Low | $4.12 | EPS | $0.00 | |||
| Volume | 78,258 | |||||
| Cache Capital Corp. (NASDAQ: CCCC) | Delayed: 4.12 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.12 | 52 Week High | $0.30 | |||
| Open | $4.12 | 52 Week Low | $0.30 | |||
| Day High | $4.12 | P/E | N/A | |||
| Day Low | $4.12 | EPS | $0.00 | |||
| Volume | 78,258 | |||||
